Company: ARTL
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001640334-25-000825
Chunk: 112

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 112
---
 Comprehensive Loss

(Unaudited)

(In thousands, except per share data)

  Three months ended   March 31,   2025  2024        OPERATING EXPENSES      General and administrative $995  $1,082 Research and development  1,384   1,507 Total Operating Expenses  2,379   2,589          Loss from Operations  (2,379)  (2,589)         OTHER INCOME         Net change in fair value of trading marketable securities  -   106 Interest income  7   - Total other income  7   106          Provision for income taxes  -   -          NET LOSS $(2,372) $(2,483)         OTHER COMPREHENSIVE LOSS        Foreign currency translation adjustments  (25)  - Total Other Comprehensive Loss  (25)  -          TOTAL COMPREHENSIVE LOSS $(2,397) $(2,483)         Basic and Diluted Loss per Common Share $(0.72) $(0.78)         Basic and Diluted Weighted Average Common Shares Outstanding  3,281   3,197 

 4Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands)

     Additional     Accumulated Other       Common stock  Paid-in  Accumulated  Comprehensive      Shares  Amount  Capital  Deficit  Loss  Total                    Balance, December 31, 2024  3,281  $3  $53,192  $(50,136) $(202) $2,857                          Stock based compensation  -   -   192   -   -   192 Net loss for the period  -   -   -   (2,372)  -   (2,372)Other comprehensive loss  -   -   -   -   (25)  (25)Balance, March 31, 2025  3,281  $3  $53,